Briacell Therapeutics Corp (BCTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.00
• Market Cap: $28.28M
• EPS: $-33.87
• 52-Week High: $60.30
• 52-Week Low: $3.60

Market Sentiment

Briacell Therapeutics Corp currently has a Bullish sentiment score of 0.63.

About Briacell Therapeutics Corp

Briacell Therapeutics Corp. is a clinical-stage biotechnology firm based in West Vancouver, Canada, specializing in personalized immunotherapy solutions for cancer, particularly breast cancer. The company is developing its proprietary platform, focusing on leveraging the immune system to effectively target tumors. Its lead candidate, Bria-imiRNA-132, aims to enhance the immune response against cancer cells, showcasing significant potential within the oncology market. With a strong emphasis on...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Briacell Therapeutics Corp and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BCTX pay dividends?

Briacell Therapeutics Corp (BCTX) does not currently pay a regular dividend.

What is BCTX's market cap?

Briacell Therapeutics Corp (BCTX) has a market capitalization of $28.28M with a current stock price of $4.00.